Post-Irradiation Hyperamylasemia Is a Prognostic Marker for Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Population: A Retrospective Single-Centre Cohort Analysis.
hematopoietic stem cell transplantation
leukemia relapse
overall survival
pediatric patients
proinflammatory cytokines
total amylase
total body irradiation
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Aug 2021
26 Aug 2021
Historique:
received:
04
07
2021
revised:
18
08
2021
accepted:
23
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Total body irradiation (TBI) is a mandatory step for patients with acute lymphoblastic leukemia (ALL), undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In the past, amylases have been reported to be a possible sign of TBI toxicity. We investigated the relationship between total amylases (TA) and transplant-related outcomes in pediatric recipients. We retrospectively analyzed the medical records of all the patients who underwent allogeneic HSCT between January 2000 and November 2019. The inclusion criteria were the following: recipient's age between 2 and 18, diagnosis of ALL, no previous transplantation, and use of TBI-based conditioning. The serum total amylase and pancreatic amylase were evaluated before, during, and after transplantation. Cytokines and chemokines assays were retrospectively performed. 78 patients fulfilled the inclusion criteria. Fifty-seven patients were treated with fractionated TBI, and 21 with a single-dose regimen. The overall survival (OS) was 62.8%. Elevated values of TA were detected in 71 patients (91%). The TA were excellent in predicting the OS (AUC = 0.773; 95% CI = 0.66-0.86; this study shows that TA is a valuable predictor of post-transplant OS and increased risk of leukemia relapse.
Sections du résumé
BACKGROUND
BACKGROUND
Total body irradiation (TBI) is a mandatory step for patients with acute lymphoblastic leukemia (ALL), undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In the past, amylases have been reported to be a possible sign of TBI toxicity. We investigated the relationship between total amylases (TA) and transplant-related outcomes in pediatric recipients.
METHODS
METHODS
We retrospectively analyzed the medical records of all the patients who underwent allogeneic HSCT between January 2000 and November 2019. The inclusion criteria were the following: recipient's age between 2 and 18, diagnosis of ALL, no previous transplantation, and use of TBI-based conditioning. The serum total amylase and pancreatic amylase were evaluated before, during, and after transplantation. Cytokines and chemokines assays were retrospectively performed.
RESULTS
RESULTS
78 patients fulfilled the inclusion criteria. Fifty-seven patients were treated with fractionated TBI, and 21 with a single-dose regimen. The overall survival (OS) was 62.8%. Elevated values of TA were detected in 71 patients (91%). The TA were excellent in predicting the OS (AUC = 0.773; 95% CI = 0.66-0.86;
CONCLUSIONS
CONCLUSIONS
this study shows that TA is a valuable predictor of post-transplant OS and increased risk of leukemia relapse.
Identifiants
pubmed: 34501281
pii: jcm10173834
doi: 10.3390/jcm10173834
pmc: PMC8432189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nature. 2015 Oct 1;526(7571):126-30
pubmed: 26416744
Cancer Control. 2008 Apr;15(2):140-50
pubmed: 18376381
Strahlenther Onkol. 2010 Nov;186(11):614-20
pubmed: 21069270
Front Oncol. 2019 Oct 01;9:987
pubmed: 31632918
Radiology. 1979 Apr;131(1):243-7
pubmed: 370902
Ann ICRP. 2018 Oct;47(3-4):126-141
pubmed: 29648458
Oncogene. 2001 Oct 25;20(48):7085-95
pubmed: 11704832
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
Crit Rev Oncol Hematol. 2018 Mar;123:138-148
pubmed: 29482775
J Cell Physiol Suppl. 1957 Dec;50(Suppl 1):123-38
pubmed: 13513683
Trends Immunol. 2001 Feb;22(2):83-7
pubmed: 11286708
Radiother Oncol. 1990;18 Suppl 1:60-7
pubmed: 2247650
Cancer. 2009 Oct 15;115(20):4715-26
pubmed: 19642176
Br J Radiol. 2015 Jul;88(1051):20150009
pubmed: 25989697
Nat Rev Dis Primers. 2019 Feb 21;5(1):13
pubmed: 30792503
Semin Radiat Oncol. 2010 Jan;20(1):21-9
pubmed: 19959028
Clin Orthop Relat Res. 1991 Feb;(263):30-48
pubmed: 1993386
Clin Transl Oncol. 2007 Jan;9(1):21-7
pubmed: 17272226
Adv Cancer Res. 2015;127:227-52
pubmed: 26093902
Cancer Cell. 2014 Jun 16;25(6):778-93
pubmed: 24937459
J Neurosci Res. 2017 Apr;95(4):1067-1078
pubmed: 27436454
Haematologica. 2017 Oct;102(10):e389-e393
pubmed: 28619846
Bone Marrow Transplant. 2020 Jan;55(1):126-136
pubmed: 31455899
Oncotarget. 2017 Jun 28;8(52):90496-90500
pubmed: 29163848
Nat Rev Cancer. 2009 Feb;9(2):134-42
pubmed: 19148183
J Clin Oncol. 2021 Feb 1;39(4):295-307
pubmed: 33332189
Cancer. 2014 Sep 1;120(17):2760-5
pubmed: 24804873
Cell Stem Cell. 2017 Aug 3;21(2):241-255.e6
pubmed: 28777945
Strahlenther Onkol. 2009 Nov;185(11):751-5
pubmed: 19899009
Radiother Oncol. 1992 May;24(1):21-6
pubmed: 1620884
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1187-94
pubmed: 15990024
Bone Marrow Transplant. 1986 Dec;1(2):151-7
pubmed: 3332129
Front Oncol. 2019 Nov 19;9:1217
pubmed: 31803612
J Bone Miner Res. 2015 Jul;30(7):1268-79
pubmed: 25588731
Health Phys. 1993 Apr;64(4):370-4
pubmed: 8449718
Adv Ther. 2017 May;34(5):1184-1199
pubmed: 28429246
Clin Chem. 1986 Apr;32(4):609-10
pubmed: 2420486
Cancer Med. 2019 Mar;8(3):890-901
pubmed: 30690926
N Engl J Med. 2007 Oct 11;357(15):1472-5
pubmed: 17928594
Transpl Int. 1991 Jun;4(2):96-8
pubmed: 1716901
Nat Rev Drug Discov. 2012 Mar 01;11(3):234-50
pubmed: 22378270